Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Mosaic Company (MOS)

Mosaic Company (MOS)
24.30 -0.38 (-1.54%) 11:54 ET [NYSE]
24.29 x 200 24.32 x 25
Realtime by (Cboe BZX)
24.29 x 200 24.32 x 25
Realtime 24.23 -0.45 (-1.82%) 09:20 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
23.99
Day High
24.59
Open 24.28
Previous Close 24.68 24.68
Volume 1,392,462 1,392,462
Avg Vol 6,042,850 6,042,850
Stochastic %K 27.09% 27.09%
Weighted Alpha -21.60 -21.60
5-Day Change -1.53 (-5.89%) -1.53 (-5.89%)
52-Week Range 22.36 - 32.66 22.36 - 32.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,822,055
  • Shares Outstanding, K 316,939
  • Annual Sales, $ 11,123 M
  • Annual Income, $ 174,900 K
  • EBIT $ 622 M
  • EBITDA $ 1,795 M
  • 60-Month Beta 1.04
  • Price/Sales 0.65
  • Price/Cash Flow 3.99
  • Price/Book 0.62

Options Overview Details

View History
  • Implied Volatility 50.69% ( +4.88%)
  • Historical Volatility 49.67%
  • IV Percentile 96%
  • IV Rank 65.55%
  • IV High 64.58% on 04/07/25
  • IV Low 24.26% on 06/05/24
  • Put/Call Vol Ratio 0.21
  • Today's Volume 2,312
  • Volume Avg (30-Day) 9,054
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 177,358
  • Open Int (30-Day) 176,430

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.38
  • Number of Estimates 7
  • High Estimate 0.51
  • Low Estimate 0.31
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -41.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.36 +9.26%
on 04/07/25
Period Open: 24.88
28.66 -14.76%
on 03/20/25
-0.45 (-1.81%)
since 03/10/25
3-Month
22.36 +9.26%
on 04/07/25
Period Open: 24.83
28.92 -15.54%
on 01/24/25
-0.40 (-1.61%)
since 01/10/25
52-Week
22.36 +9.26%
on 04/07/25
Period Open: 32.68
32.66 -25.20%
on 04/11/24
-8.25 (-25.24%)
since 04/10/24

Most Recent Stories

More News
Reasons Why You Should Hold Mosaic Stock in Your Portfolio Now

The Mosaic Company MOS gains on favorable demand for phosphate and potash, high-return investments and actions to improve its cost structure amid headwinds from soft fertilizer prices.MOS’s shares are...

MOS : 24.30 (-1.54%)
CRS : 167.72 (-4.18%)
IDR : 16.19 (+2.79%)
DRD : 15.38 (+8.54%)
FMC Corporation Stock: Is FMC Underperforming the Material Sector?

FMC Corporation has failed to keep up with the material sector over the past year, and analysts are maintaining a moderately optimistic outlook on the stock’s prospects.

MOS : 24.30 (-1.54%)
FMC : 35.54 (-4.64%)
XLB : 77.66 (-3.84%)
Is Mosaic Company Stock Underperforming the Dow?

Although Mosaic Company has underperformed the Dow Jones Industrial Average over the past year, Wall Street analysts continue to hold a moderately optimistic view on the stock's prospects.

MOS : 24.30 (-1.54%)
CF : 70.12 (-0.54%)
$DOWI : 39,246.42 (-3.35%)
Mosaic's Shares Rise 11% in 3 Months: What's Driving the Stock?

The Mosaic Company’s MOS shares have gained 10.8% over the past three months. The company has also outperformed the Zacks Fertilizers industry’s 3.9% rise over the same time frame. Let’s take a...

MOS : 24.30 (-1.54%)
NGVT : 30.99 (-7.22%)
CRS : 167.72 (-4.18%)
AXTA : 30.01 (-5.51%)
CF Industries Stock: Is CF Underperforming the Material Sector?

CF Industries has lagged behind the broader materials sector in recent years, with analysts maintaining a cautious outlook on its prospects.

MOS : 24.30 (-1.54%)
CF : 70.12 (-0.54%)
XLB : 77.66 (-3.84%)
Stocks Settle Higher as Magnificent Seven Stocks Climb

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.53%. June E-mini S&P...

GOOGL : 153.00 (-3.60%)
AAPL : 187.65 (-5.63%)
IPI : 26.22 (-1.21%)
MBLY : 12.96 (-14.40%)
UNF : 169.04 (-2.35%)
$IUXX : 18,280.81 (-4.51%)
DJT : 18.87 (-6.91%)
ZNM25 : 110-295 (+0.54%)
MSFT : 375.91 (-3.73%)
KBH : 51.48 (-4.74%)
TSLA : 246.55 (-9.42%)
ESM25 : 5,269.25 (-4.04%)
Announcing The Mosaic Company Foundation for Sustainable Food Systems

MOS : 24.30 (-1.54%)
Stocks Push Higher on Strength in Magnificent Seven Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.48%. June E-mini S&P futures (ESM25...

GOOGL : 153.00 (-3.60%)
AAPL : 187.65 (-5.63%)
IPI : 26.22 (-1.21%)
MBLY : 12.96 (-14.40%)
UNF : 169.04 (-2.35%)
$IUXX : 18,280.81 (-4.51%)
DJT : 18.87 (-6.91%)
ZNM25 : 110-295 (+0.54%)
MSFT : 375.91 (-3.73%)
KBH : 51.48 (-4.74%)
ESM25 : 5,269.25 (-4.04%)
$DOWI : 39,246.42 (-3.35%)
Mosaic Announces Quarterly Dividend of $0.22 Per Share

TAMPA, FL / ACCESS Newswire / March 20, 2025 / The Mosaic Company (NYSE:MOS) announced today that its Board of Directors declared a quarterly dividend of $0.22 per share on the Company's common stock....

MOS : 24.30 (-1.54%)
Here's Why You Should Retain Mosaic Stock in Your Portfolio

The Mosaic Company MOS benefits from healthy demand for phosphate and potash, high-return investments and actions to improve its cost structure amid headwinds from soft fertilizer prices.MOS’ shares...

MOS : 24.30 (-1.54%)
NGVT : 30.99 (-7.22%)
CRS : 167.72 (-4.18%)
AXTA : 30.01 (-5.51%)
AnaptysBio Discontinues ANB032 Development After Phase 2a Trial Fails to Meet Efficacy Endpoints

AnaptysBio halts ANB032 investment after ineffective trial results; focuses on other assets, with cash runway through 2027.Quiver AI SummaryAnaptysBio, Inc. announced that its investigational drug ANB032,...

ANAB : 15.97 (-5.50%)
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANAB : 15.97 (-5.50%)
Anaptys Announces Participation in November and December Investor Conferences

ANAB : 15.97 (-5.50%)
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

ANAB : 15.97 (-5.50%)
Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

ANAB : 15.97 (-5.50%)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 63.03 (-4.98%)
LLY : 704.98 (-6.47%)
ANAB : 15.97 (-5.50%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 542.28 (-3.87%)
ABBV : 168.00 (-6.58%)
ABCL : 2.00 (-8.06%)
ALNY : 221.67 (-8.88%)
AMGN : 274.97 (-5.54%)
ANAB : 15.97 (-5.50%)
AZN : 64.11 (-3.97%)
BMY : 50.18 (-6.62%)
INCY : 55.08 (-6.42%)
REGN : 542.98 (-5.85%)
VIE : 53.01 (unch)
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies...

ANAB : 15.97 (-5.50%)
AnaptysBio Discontinues ANB032 Development After Phase 2a Trial Fails to Meet Efficacy Endpoints

AnaptysBio halts ANB032 investment after ineffective trial results; focuses on other assets, with cash runway through 2027.Quiver AI SummaryAnaptysBio, Inc. announced that its investigational drug ANB032,...

ANAB : 15.97 (-5.50%)
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANAB : 15.97 (-5.50%)
Anaptys Announces Participation in November and December Investor Conferences

ANAB : 15.97 (-5.50%)
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

ANAB : 15.97 (-5.50%)
Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

ANAB : 15.97 (-5.50%)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 63.03 (-4.98%)
LLY : 704.98 (-6.47%)
ANAB : 15.97 (-5.50%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 542.28 (-3.87%)
ABBV : 168.00 (-6.58%)
ABCL : 2.00 (-8.06%)
ALNY : 221.67 (-8.88%)
AMGN : 274.97 (-5.54%)
ANAB : 15.97 (-5.50%)
AZN : 64.11 (-3.97%)
BMY : 50.18 (-6.62%)
INCY : 55.08 (-6.42%)
REGN : 542.98 (-5.85%)
VIE : 53.01 (unch)
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies...

ANAB : 15.97 (-5.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

The Mosaic Company is a leading producer and marketer of concentrated phosphate and potash for the global agriculture industry. It was formed through the combination of the fertilizer businesses of agribusiness giant Cargill Incorporated and IMC Global Inc. Mosaic is the biggest integrated phosphate...

See More

Key Turning Points

3rd Resistance Point 28.39
2nd Resistance Point 26.76
1st Resistance Point 25.72
Last Price 24.30
1st Support Level 23.05
2nd Support Level 21.42
3rd Support Level 20.38

See More

52-Week High 32.66
Fibonacci 61.8% 28.73
Fibonacci 50% 27.51
Fibonacci 38.2% 26.29
Last Price 24.30
52-Week Low 22.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.